Stem cell factor and chronic myeloid leukemia CD34+ cells

Leukemia and Lymphoma

Volumn 38, Issue 3-4, 2000, Pages 211-220

  Moore, Sarah ^a,b   McDiarmid, Louise A ^a   Hughes, Timothy P ^a  

^a HANSON INSTITUTE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

CD34+ cells; Chronic myeloid leukemia; CML; SCF; Stem cell factor

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; CYTOKINE; FIBRONECTIN; STEM CELL FACTOR;

BONE MARROW; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT GM; HEMATOPOIESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REVIEW; SPLEEN;

EID: 0034077150     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009087013     Document Type: Review

References (66)

1. Shtivelman E, Lifshitz B, Gale RP, Canaani E. (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315:550-554.
2. Bedi A, Zehnbauer RA, Barber JP, Sharkis SJ, Jones RJ. (1994) Inhibition of apoptosis by BCR-ABL in chronic myelogenous leukemia. Blood, 83, 2038-2044.
3. Amos TAS, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY. (1995) Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. British Journal of Haematology, 91, 387-393.
4. Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky WE. (1996) Primary proliferating immature myeloid cells from CML Patients are not resistant to induction apoptosis by DNA damage and growth factor withdrawal. British Journal of Haematology, 95, 501-507.
5. Gordon MY, Dazzi F, Marley SB, Lewis JL, Nguyen D, Grand FH, Davidson RJ, Goldman JM. (1999) Cell biology of CML cells. Leukemia, Suppl. 1, S65-S71.
6. Raskind WH, Fialkow PJ. (1987) The use of cell markers in the study of human hematopoietic neoplasia. Advances in Cancer Research, 49, 127-67.
7. Strife A, Lambek C, Wisniewski D, Wachter M, Gulati SC, Clarkson BD. (1988) Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Research, 48, 1035-1041.
8. Stryckmans PA, Debusscher L, Collard E. (1977) Cell kinetics in chronic granulocytic leukaemia (CGL). Clinical Haematology, 6, 21-40.
9. Pedersen B. (1982) Kinetics and cell function. In Chronic Granulocytic Leukemia, edited by M.T. Shaw, pp. 93-135. Eastbourne, New York. Praeger Scientific Publishers.
10. Thiele J, Zirbes TK, Lorenzen J, Kvasnicka HM, Dresbach S, Munich B, Leder LD, Niederle N, Diehl V, Fischer R. (1997) Apoptosis and proliferation (PCNA labelling) in CML: a comparative immunohistological study of bone marrow biopsies following interferon and busulphan therapy. Journal of Pathology, 181, 316-322.
11. Eaves CJ and Eaves AC. (1997) Stem Cell Kinetics. In Bailliere's Clinical Haematology, 10, 233-257.
12. Veena P, Cornetta K, Davidson A, Aguero B, McMahal J, Traycoff C, Srour E. (1997) Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells. Bone Marrow Transplantation, 19, 1213-1221.
13. 1 phases of cell cycle more rapidly than normal marrow CD34+ cells. British Journal of Haematology, 102, 759-767.
14. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. (1987) Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature, 328, 342-344.
15. Verfaillie CM, McCarthy JB, McGlave PB. (1992) Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. Journal of Clinical Investigation, 90, 1232-1241.
16. Bhatia R, Munthe HA, Verfaillie CM. (1999) Role of abnormal integrin-cytoskeletal interactions in impaired beta 1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Experimental Hematology 27, 1384-1396.
17. Kovach NL, Lin N, Yednock T, Harlan JM, Broudy VC. (1995) Stem cell factor modulates avidity of α4β1 and α5β1 integrins expressed on hematopoietic cell lines. Blood, 85, 159-167.
18. Lévesque J-P, Leavesley DI, Niutta S, Vadas M, Simmons PJ. (1995) Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. Journal of Experimental Medicine, 181, 1805-1815.
19. Cashman JD, Eaves CJ, Sarris AH, Eaves AC. (1998) MCP-1, not MIP-1α, is the endogenous chemokine that cooperates with TGF-β to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood, 92, 2338-2344.
20. Upadhyaya G, Guba S, Sih S, Feinberg A, Talpaz M, Kantarjian H, Deisseroth A, Emerson S. (1991) Interferon-alpha restores the deficient expression of the cyto-adhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. Journal of Clinical Investigation, 88, 2131-2136.
21. Ghaffari S, Dougherty GJ, Eaves AC, Eaves CJ. (1997) Diverse effects of anti-CD44 antibodies on the stromal cell-mediated support of normal but not leukaemic (CML) haematopoiesis in vitro. British Journal of Haematology, 97, 22-28.
22. Moore S, Haylock DN, Lévesque JP, McDiarmid LA, Samels LM, To LB, Simmons PJ, Hughes TP. (1998) Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of CML CD34+ cells. Blood, 92, 2461-2470.
23. Fogli M, Amabile M, Martinelli G, Fortuna A, Rondelli D, Ratta M, Curti A, Tura S, Lemoli RM. (1998) Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. British Journal of Haematology, 101, 119-129.
24. Argawal R, Doren S, Hicks B, Dunhar CE (1995) Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor deficient stroma favors benign progenitors. Blood, 85, 1306-1312.
25. bcr/abl kinase in myeloid cells. British Journal of Haematology, 94, 5-16.
26. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO Journal, 6, 3341-3351.
27. Qui F, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, Besmer P. (1988) Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family- oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO Journal, 7, 1003-1011.
28. Birg F, Courcoul M, Rosnet O, Bardin F, Pebusque MJ, Marchetto S, Tabilio A, Mannoni P, Birnbaum D. (1992) Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood, 80, 2584-2593.
29. Wang C, Curtis JE, Geissler EN, McCulloch EA, Minden MD. (1989) The expression of the proto-oncogene c-kit in the blast cells of acute myeloblastic leukemia. Leukemia, 3, 699-702.
30. Mayrhofer G, Gadd SJ, Spargo LDJ, Ashman LK. (1987) Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues. Immunology and Cell Biology, 65, 241-250.
31. Majumder S, Brown K, Qui FH, Besmer P. (1988) C-kit protein, a transmembrane kinase: Identification in tissues and characterization. Molecular and Cellular Biology, 8, 4896-4903.
32. Nocka K, Majumder S, Chabot B, Ray M, Cervone A, Bernstein A, Besmer P. (1994) Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - evidence for an impaired c-kit kinase in mutant mice. Genes & Development, 3, 816-826.
33. Matos ME, Schnier GS, Beecher MS, Ashman LK, William DE, Caligiuri MA. (1993) Expression of a functional c-kit receptor on a subset of natural killer cells. Journal of Experimental Medicine, 178, 1079-1084.
34. Grabarek J, Groopman JE, Lyles YR, Jiang S, Bennett L, Zsebo K, Avraham H. (1994) Human kit ligand (stem cell factor) modulates platelet activation in vitro. Journal of Biological Chemistry, 269, 21718-21724.
35. Broudy VC, Kovach NL, Bennett LG, Lin N, Jacobsen FW, Kidd PG. (1994) Human umbilical vein endothelial cells display high affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood, 83, 2145-2152.
36. Torihashi S, Ward SM, Nishikawa SI, Nishi K, Kobayashi S, Sanders KM. (1995) C-kit dependent development if interstitial cells and electrical activity in the murine gastrointestinal tract. Cell and Tissue Research, 280, 97-111.
37. Huizinga JD, Thuneberg L, Klueppel M, Malysz J Mikkelsen HB, Bernstein A. (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature, 373, 347-349.
38. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A. (1992) Expression of the c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Research, 52, 6139-6143.
39. Lammie A, Drohnjak M, Gerald W, Saad A, Cote R, Cordon-Cado C. (1994) Expression of c-kit and kit-ligand proteins in normal human tissues. Journal of Histochemistry and Cytochemistry, 42, 1417-1425.
40. Blechman JM, Lev S, Brizzi MF, Leitner O, Pegoraro L, Givol D, Yarden Y. (1993) Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. Journal of Biological Chemistry, 268, 4399-4406.
41. Blechman JM, Lev S, Barg J, Eisenstein M, Vaks B, Vogel Z, Givol D, Yarden Y (1995) The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell. 80, 103-113.
42. Van der Geer P, Hunter T, Lindberg RA. (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annual Review of Cell Biology, 10, 251-337.
43. Wisniewski D, Strife A, Berman E, Clarkson B. (1996) c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phophotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia. Leukemia, 10, 229-237.
44. Clarkson BD, Strife A, Wisniewski D, Lambek C, Carpino N. (1997) New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia, 11, 1404-1428.
45. Heinrich MC, Dooley DC, Freed AC, Band L, Hoatlin ME, Keeble WW, Peters ST, Silvey KV, Ey FS, Kahat D, et al. (1993) Constitutive expression of steel factor gene by human stromal cells. Blood, 82, 771-783.
46. Caruanu G, Ashman LK, Fujita J and Gonda TJ. (1993) Responses of the murine myeloid cell line FDC-P1 to soluble and membrane forms of steel factor (SLF). Experimental Hematology, 21, 761-768.
47. Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K. (1995) Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene encoded protein than its soluble form. Blood, 85, 641-649.
48. Fujita J, Onoue H, Ebi Y, Nakayama H, Kanakura Y. (1989) In vitro duplication and in vivo cure of mast cell deficiency of Sl/Sld mutant mice by cloned 3T3 fibroblasts. Proceedings of the National Academy of Sciences (USA), 86, 2888-2891.
49. Toksoz D, Zsebo KM, Smith KA, Hu S, Brankow D, Suggs SV, Martin FH Williams DA. (1992) Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane hound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proceedings of the National Academy of Sciences (USA), 89, 7350-7354.
50. Kapur R, Majumdar M, Xiao XG, McAdrews-Hill M, Schindler K, Williams DA. (1998) Signalling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: Genetic evidence for a differential role in erythropoiesis. Blood, 91, 879-889.
51. Gore SD, Amin S, Weng LJ, Civin CI. (1995) Steel factor supports the cycling of isolated human CD34+ cells in the absence of other growth factors. Experimental Hematology, 23, 413-421.
52. Issaad C, Vainchenker W. (1994) Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor. Blood, 84, 3447-3456.
53. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitumura Y, Kanakura Y. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand independent activation of c-kit product. Journal of Clinical Investigation, 92, 1736-1744.
54. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, and Modlin I. (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nature Genetics, 12, 312-314.
55. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tananbaum S, Suzuki Y, Metcalf DD. (1995) Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Procedings of the National Academy of Science, 92, 10560-10564.
56. Pignon JM, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W, Vernant JP, Tulliez M. (1997) A new c-kit mutation in a case of aggressive mast cell disease. British Journal of Haematology, 96, 374-376.
57. Kimura A, Nakata Y, Katoh O, Hyodo H, (1997) C-kit point mutation in patients with myeloproliferative disorders. Leukemia and Lymphoma 25, 281-287.
58. Beghini A, Larizza L, Cairoli R, Morra E. (1998) In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells Mol. Dis., 24, 262-270.
59. Ashman LK, Ferrrao P, Cole SR, Camareri AC. (1999) Effects of mutant c-kit in early myeloid cells. Leukemia and Lymphoma, 34, 451-461.
60. Cole SR, Aylett GW, Casey G, Harvey NL, Cambareri AC, Ashman LK. (1996) Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukemia. Leukemia, 10, 288-296.
61. Jiang X, Eaves A, Eaves C. (1997) IL-3 and G-CSF gene expression in primitive Ph+ CD34+ cells from patients with chronic myeloid leukemia (CML). Blood, 90, 392a, (abstr).
62. Zhang X, Ren R. (1998) Bcr-Abl efficiently induces myeloproliterative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukaemia. Blood, 92, 3829-3840.
63. Dunbar CE, Browder TM, Abrams JS, Nienhuis AW. (1989) COOH-Terminal-Modified Interleukin-3 is retained intracellullarly and stimulates autocrine growth. Science, 245, 1493-1496.
64. Mahon FX, Pigoennier-Lagarde V, Chahine H, Barbot C, Jazwiec B, Ripoche J, Reiffers J. (1997) Ex vivo cytokine expansion of peripheral blood 5-fluorouracil-treated CD34-positive chronic myeloid leukaemia cells increases the selection of Ph-negative cells. British Journal of Haematology, 98, 467-473.
65. Holyoake T, Jiang X, Eaves C, Eaves A. (1999) Isolation of a highly quiescent subpopulation of primitive leukuemic cells in chronic myeloid leukemia. Blood, 94, 2056-2064.
66. Sawyers CL, Druker B. (1999) Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer Journal from Scientific American, 5, 63-69.